二肽基肽酶-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-29. Anything still debated is marked as such rather than presented as settled.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分子量 | 约 4113.6 道尔顿 | 游离碱形式，随反离子略有差异 |
| 外观 | 白色至类白色冻干粉末 | 具吸湿性，需干燥保存 |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | 溶解性随 pH 升高而改善 |
| 等电点 | 约 5.4 | 影响缓冲液选择与聚集倾向 |
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
=== Sleeping sickness treatment === The drug was registered for the treatment of gambiense sleeping sickness on 28 November 1990. However, in 1995 Aventis (now Sanofi-Aventis) stopped producing the drug, whose main market was African countries, because it did not make a profit. In 2001, Aventis and the WHO formed a five-year partnership, during which more than 320,000 vials of pentamidine, over 420,000 vials of melarsoprol, and over 200,000 bottles of eflornithine were produced by Aventis, to be given to the WHO and distributed by the association Médecins sans Frontières (also known as Doctors Without Borders) in countries where sleeping sickness is endemic. According to Médecins sans Frontières, this only happened after "years of international pressure," and coinciding with the period when media attention was generated because of the launch of another eflornithine-based product (Vaniqa, for the prevention of facial-hair in women), while its life-saving formulation (for sleeping sickness) was not being produced.
=== 1988 === February 20: The First Nagorno-Karabakh War was fought between Armenia and Azerbaijan. February 22: USS Yorktown and USS Caron are rammed off the Crimean Peninsula after entering Soviet territorial waters. May 11: Kim Philby (Harold Adrian Russell Philby), the high-ranking UK intelligence officer who defected to the Soviet Union, dies in Moscow. May 15: The Soviets begin withdrawing from Afghanistan. May 29–June 1: Reagan and Gorbachev meet in Moscow. INF Treaty ratified. When asked if he still believes that the Soviet Union is still an evil empire, Reagan replies he was talking about "another time, another era". October 5: Chile's Augusto Pinochet loses a national plebiscite on his rule. November 3: A coup attempt occurred in the Maldives. November 6: Soviet scientist and well-known human rights activist Andrei Sakharov begins a two-week visit to the United States. November 15: The State of Palestine was formally established through the Palestinian Declaration of Independence. December 7: Gorbachev announces in a speech to the United Nations General Assembly that the Soviet Union will no longer militarily interfere with Eastern Europe.
=== Early pumps === The predecessor to the vacuum pump was the suction pump. Dual-action suction pumps were found in the city of Pompeii. The Arab engineer Al-Jazari later described dual-action suction pumps as part of water-raising machines in the 13th century. He also said that a suction pump was used in siphons to discharge Greek fire. The suction pump later appeared in medieval Europe from the 15th century.
=== EC 2.8.1: Sulfurtransferases === EC 2.8.1.1: thiosulfate sulfurtransferase EC 2.8.1.2: 3-mercaptopyruvate sulfurtransferase EC 2.8.1.3: thiosulfate—thiol sulfurtransferase EC 2.8.1.4: tRNA sulfurtransferase EC 2.8.1.5: thiosulfate—dithiol sulfurtransferase EC 2.8.1.6: biotin synthase EC 2.8.1.7: cysteine desulfurase EC 2.8.1.8: lipoyl synthase EC 2.8.1.9: molybdenum cofactor sulfurtransferase EC 2.8.1.10: thiazole synthase EC 2.8.1.11: molybdopterin synthase sulfurtransferase EC 2.8.1.12: molybdopterin synthase EC 2.8.1.13: tRNA-uridine 2-sulfurtransferase EC 2.8.1.14: tRNA-5-taurinomethyluridine 2-sulfurtransferase EC 2.8.1.15: tRNA-5-methyluridine54 2-sulfurtransferase EC 2.8.1.16: L-aspartate semialdehyde sulfurtransferase
Using the money from her portraits, Jolene leaves and boards a bus west out of South Carolina. Jolene resorts to hitchhiking further west, supporting herself by prostitution. Jolene ends up in Arizona, working as a waitress at an outdoor diner. There, she meets Coco Leger, an aspiring musician and tattoo artist. A relationship blossoms between them and Jolene becomes a tattoo artist at Coco's parlor. After two weeks of dating, Jolene moves in with Coco and he convinces her to get married. After he passes out during sex, Coco is revealed to have a cocaine addiction, supporting his habit and the parlor by dealing cocaine. One evening, a young woman enters the parlor and declares herself to be his wife, Marin and introduces their son, Coco Jr. Coco returns and is confronted by both women before he walks out with Marin and the baby. Furious with Coco, Jolene destroys the parlor, dumps the cocaine on a table, steals the drug money and dumps her ring in the center of the cocaine before dialing 911 and fleeing the scene. Jolene later is in Las Vegas, working as an erotic dancer when she meets Sal Fontaine, a mobster. He takes a liking to her and invites her to quit dancing and move into his high rise condo. Jolene enjoys a life of luxury with Sal, going to fancy dinners and exploring her talent as an artist. One night, Sal demands that Jolene get dressed, go downstairs and wait for him. She falls asleep in the restaurant and quietly returns to the condo to find Sal dead and the mob looking for her. Jolene escapes and ends up hitchhiking on a truck to Tulsa.
Sources: en.wikipedia.org
== Awards == 2023 Tung-Ho Outstanding Research Award, THS Foundation 2023 16th Taiwan Outstanding Women in Science Awards, Wu Chien Shiung Education Foundation & L'ORÉAL Taiwan 2022 Outstanding Research Award, National Science and Technology Council 2022 Outstanding Research Award, National Science and Technology Council 2021 National Innovation Award 2020 Taiwan Society for Mass Spectrometry Medal 2011 Taiwan Society for Mass Spectrometry Outstanding Scholar Award 2007 Federation of Asian Chemical Societies Distinguished Young Chemists Award 2006 Chinese Chemical Society Outstanding Young Investigator Award
Researchers reported numerous "chemical strains" or chemotypes: lichens identical in appearance yet separable by their metabolites. For instance, MacKenzie (1951) noted that morphologically identical Stereocaulon tomentosum forms differed in chemistry—one containing stictic acid, the other fumarprotocetraric acid. These chemotypes often occupy different regions or microhabitats, and breeding or DNA data have since supported treating them as separate species. Metabolite profiles also informed higher-level classification. In some cases, entire genera were defined or redefined by their chemical profiles. In the Cetraria group, species rich in specific fatty acids were placed in Platismatia, whereas taxa containing orcinol depsidones were transferred to Cetrelia; the shift was consistent with their chemical differences. Chemical data further resolved misclassifications based solely on morphology. For example, species formerly combined in Anaptychia were divided after researchers noted that forms with thick-walled spores and a medulla containing zeorin plus specific depsidones formed a coherent group (Heterodermia), whereas thin-walled, chemically simpler taxa stayed in Anaptychia.
Programmed cell death in plants has a number of molecular similarities to that of animal apoptosis, but it also has differences, notable ones being the presence of a cell wall and the lack of an immune system that removes the pieces of the dead cell. Instead of an immune response, the dying cell synthesizes substances to break itself down and places them in a vacuole that ruptures as the cell dies. Additionally, plants do not contain phagocytic cells, which are essential in the process of breaking down and removing apoptotic bodies. Whether this whole process resembles animal apoptosis closely enough to warrant using the name apoptosis (as opposed to the more general programmed cell death) is unclear.
Selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq) is a technique developed for the rapid identification of DNA binding specificities and affinities of full length monomeric and dimeric transcription factors in a fast and semi-high-throughput fashion. SMiLE-seq works by loading in vitro transcribed and translated “bait” transcription factors into a microfluidic device in combination with DNA molecules. Bound transcription factor-DNA complexes are then isolated from the device, which is followed by sequencing and then sequence data analysis to characterize binding motifs. Specialized software is used to determine the DNA binding properties of monomeric or dimeric transcription factors to help predict their in vivo DNA binding activity. SMiLE-seq combines three important functions differing from existing techniques: (1) The use of capillary pumps to optimize the loading of samples, (2) Trapping molecular interactions on the surface of the microfluidic device through immunocapture of target transcription factors, (3) Enabling the selection of DNA that is specifically bound to transcription factors from a pool of random DNA sequences.
The COVID-19 Immunity Task Force (CITF) was one of the Government of Canada's early efforts to track the 2020 coronavirus pandemic. An external, dedicated secretariat was established in order to maximize the efficiency of the CITF's work. The group terminated its mandate on March 31, 2024. The group terminated its mandate on March 31, 2024. During the four-year period, the CITF provided several purposes and uses for the general Canadian population. The CITF was to use a serology "to survey representative samples of the population for the presence of antibodies to the virus". Trudeau's press release on 23 April 2020, on the initiation of the CCITF listed several goals it would help to achieve notably that it would: establish priorities and oversee the coordination of a series of country-wide blood test surveys that will tell us how widely the virus has spread in Canada and provide reliable estimates of potential immunity and vulnerabilities in Canadian populations. Canada's government funded more than $1 billion for research into how to combat COVID-19 through the CITF.
Sources: en.wikipedia.org
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。
胰岛素释放需要细胞内环腺苷酸与钙信号升高，同时依赖葡萄糖代谢产生的协同信号。血糖水平较低时协同信号不足，分泌增强有限。这一机制在降糖效果与低血糖风险之间提供了缓冲。
白蛋白结合是主要原因，它减少肾小球滤过并保护分子免受蛋白酶降解。序列修饰带来的酶解抵抗同样不可忽略，二者共同作用。脂肪链的疏水性还会影响组织分布，但其对总半衰期的贡献程度仍在研究之中。
Different techniques detect different classes of impurities, so a single number does not describe a sample completely. Reversed-phase chromatography resolves related peptides well but can miss inorganic salts, while mass spectrometry confirms mass without quantifying everything present. Comparing results requires knowing which method was used and how it was validated.